Importance Patient-reported outcomes in the treatment of opioid dependence may differ
between subcutaneously administered depot buprenorphine and daily sublingual …

Although there is general consensus that altered brain structure and function underpins
addictive disorders, clinicians working in addiction treatment rarely incorporate neuroscience-…

Background: The coronavirus disease 2019 (COVID-19) pandemic has impacted people
with substance use disorders (SUDs) worldwide, and healthcare systems have reorganized …

Objective To compare changes in pregabalin prescribing and misuse‐related ambulance
attendances; to characterise the patients attended by paramedics for pregabalin misuse‐…

Background and aims Although the prevalence of gamma‐hydroxybutyrate (GHB) use is
relatively low globally, harms related to the drug appear to be increasing. Few existing studies …

Background: Psychosocial responses to infectious disease outbreaks have the potential to
inflict acute and longstanding mental health consequences. Early research across the globe …

The COVID-19 pandemic has presented challenges for traditional models of opioid use disorder
treatment worldwide. Depot buprenorphine became available in Australia shortly before …

Background The use of amphetamines is a global public health concern. We summarise global
data on use of amphetamines and mental health outcomes. Methods A systematic review …

Background and Aims: COVID-19 has infected more than 77 million people worldwide and
impacted the lives of many more, with a particularly devastating impact on vulnerable …

Objective: Chronic methamphetamine use is commonly associated with the development of
psychotic symptoms. The predictors and correlates of methamphetamine-associated …